Email Alert | RSS

Journal of Peking University (Health Sciences) ›› 2026, Vol. 58 ›› Issue (2): 423-430. doi: 10.19723/j.issn.1671-167X.2026.02.031

Previous Articles     Next Articles

Research progress on protein lactylation modification in malignant tumors

Haifeng DONG, Hengxing CHEN, Changhua ZHANG*()   

  1. Digestive Disease Center, The Seventh Affiliated Hospital, Sun Yat-sen University; Guangdong Provincial Key Laboratory of Digestive Cancer Research, Shenzhen 518000, Guangdong, China
  • Received:2025-12-01 Online:2026-04-18 Published:2026-02-06
  • Contact: Changhua ZHANG
  • Supported by:
    the National Natural Science Foundation of China(82573049); The Guangdong Basic and Applied Basic Research Foundation(2025B1515020095); The Sanming Project of Medicine in Shenzhen(SZSM202411013); The Sanming Project of Medicine in Shenzhen(SZSM202411023); The Shenzhen Fundamental Research Program(JCYJ20240813150212017); The Shenzhen Clinical Research Center for Gastroenterology (Gastrointestinal Surgery)(LCYSSQ20220823091203008); The Research Start-up Fund of the Seventh Affiliated Hospital, Sun Yat-sen University(ZSQYRSSFAR0008)

RICH HTML

   

PDF (PC)

Abstract:

Malignant tumors, a class of diseases characterized by abnormal proliferation and aggressive growth, pose a severe threat to human health. A hallmark of tumor cell biology is the pervasive presence of the Warburg effect, wherein cells undergo high-rate glycolysis leading to substantial lactate production, even under aerobic conditions. Traditionally regarded merely as a metabolic waste product, lactate has been re-evaluated through recent research, which reveals it to be not only a crucial metabolite but also a significant signaling molecule. It exerts core regulatory functions in gene expression and cellular activity through a novel post-translational modification: Protein lactylation. The seminal discovery of histone lactylation unveiled a direct and novel mechanistic link between cellular metabolic states and epigenetic regulation. Subsequent proteomic studies have substantiated that lactylation is a widespread modification existing across various types of non-histone proteins, establishing it as an important regulatory mechanism. The process of lactylation modification is dynamic and reversible, orchestrated by specific "writer" enzymes that catalyze its addition and "eraser" enzymes that facilitate its removal. Within the context of malignant tumors, lactylation modification participates extensively in tumorigenesis and progression by targeting two primary classes of substrate proteins: Histones and non-histone proteins. At the epigenetic level, histone lactylation remodels chromatin state and reprograms gene expression profiles. At the functional level, lactylation of non-histone proteins directly modulates the activity of key signaling pathway components, metabolic enzymes, and DNA repair factors. The synergistic action of these two facets collectively drives core malignant phenotypes, including remodeling of the tumor immune microenvironment, facilitation of metastasis and dissemination, induction of therapy resistance, and dysregulation of metabolism. This review provides a systematic overview of the discovery, molecular mechanisms, and recent advances concerning the roles of lactylation in tumor metabolism, immunity, and treatment resistance. It further explores potential therapeutic strategies targeting lactylation, such as modulating lactate metabolism, intervening in the enzymatic machinery of the modification system, and developing specific blocking agents. Although challenges remain regarding the specificity of the involved enzymes and the functional validation of these modifications, in-depth research on lactylation offers a fresh perspective for understanding the crosstalk between tumor metabolism and epigenetics. It also lays a theoretical foundation for the development of innovative strategies for cancer diagnosis and therapy.

Key words: Lactylation, Tumor, Lactate, Post-translational modification, Epigenetic

CLC Number: 

  • R730.2

Figure 1

Mechanism of protein lactylation and its key functions in malignant tumors Lac, lactate; TME, tumor microenvironment."

1
Brooks GA , Osmond AD , Arevalo JA , et al. Lactate as a myokine and exerkine: Drivers and signals of physiology and metabolism[J]. J Appl Physiol, 2023, 134 (3): 529- 548.

doi: 10.1152/japplphysiol.00497.2022
2
Certo M , Llibre A , Lee W , et al. Understanding lactate sensing and signalling[J]. Trends Endocrinol Metab, 2022, 33 (10): 722- 735.

doi: 10.1016/j.tem.2022.07.004
3
Li X , Yang Y , Zhang B , et al. Lactate metabolism in human health and disease[J]. Signal Transduct Target Ther, 2022, 7 (1): 305.

doi: 10.1038/s41392-022-01151-3
4
Brooks GA . Lactate as a fulcrum of metabolism[J]. Redox Biol, 2020, 35, 101454.

doi: 10.1016/j.redox.2020.101454
5
Hou X , Hong Z , Zeng H , et al. Lactylation in cancer biology: Unlocking new avenues for research and therapy[J]. Cancer Commun, 2025, 45 (11): 1367- 1406.

doi: 10.1002/cac2.70054
6
Wishart DS . Is cancer a genetic disease or a metabolic disease?[J]. EBioMedicine, 2015, 2 (6): 478- 479.

doi: 10.1016/j.ebiom.2015.05.022
7
Racker E . Bioenergetics and the Problem of Tumor Growth: An understanding of the mechanism of the generation and control of biological energy may shed light on the problem of tumor growth[J]. Am Sci, 1972, 60 (1): 56- 63.
8
de la Cruz-López KG , Castro-Muñoz LJ , Reyes-Hernández DO , et al. Lactate in the regulation of tumor microenvironment and therapeutic approaches[J]. Front Oncol, 2019, 9, 1143.

doi: 10.3389/fonc.2019.01143
9
Zhang D , Tang Z , Huang H , et al. Metabolic regulation of gene expression by histone lactylation[J]. Nature, 2019, 574 (7779): 575- 580.

doi: 10.1038/s41586-019-1678-1
10
Sun L , Zhang H , Gao P . Metabolic reprogramming and epigenetic modifications on the path to cancer[J]. Protein Cell, 2022, 13 (12): 877- 919.

doi: 10.1007/s13238-021-00846-7
11
Yao W , Hu X , Wang X . Crossing epigenetic frontiers: The intersection of novel histone modifications and diseases[J]. Signal Transduct Target Ther, 2024, 9 (1): 232.

doi: 10.1038/s41392-024-01918-w
12
Li Y , Zhang R , Hei H . Advances in post-translational modifications of proteins and cancer immunotherapy[J]. Front Immunol, 2023, 14, 1229397.

doi: 10.3389/fimmu.2023.1229397
13
Xu H , Wu M , Ma X , et al. Function and mechanism of novel histone posttranslational modifications in health and disease[J]. Biomed Res Int, 2021, 2021, 6635225.

doi: 10.1155/2021/6635225
14
Fu Y , Yu J , Li F , et al. Oncometabolites drive tumorigenesis by enhancing protein acylation: From chromosomal remodelling to nonhistone modification[J]. J Exp Clin Cancer Res, 2022, 41 (1): 144.

doi: 10.1186/s13046-022-02338-w
15
Wan N , Wang N , Yu S , et al. Cyclic immonium ion of lactyl-lysine reveals widespread lactylation in the human proteome[J]. Nat Meth, 2022, 19 (7): 854- 864.

doi: 10.1038/s41592-022-01523-1
16
Yang YH , Wang QC , Kong J , et al. Global profiling of lysine lactylation in human lungs[J]. Proteomics, 2023, 23 (15): e2200437.

doi: 10.1002/pmic.202200437
17
Wu X . In-depth discovery of protein lactylation in hepatocellular carcinoma[J]. Proteomics, 2023, 23 (9): e2300003.

doi: 10.1002/pmic.202300003
18
Hong H , Chen X , Wang H , et al. Global profiling of protein lysine lactylation and potential target modified protein analysis in hepatocellular carcinoma[J]. Proteomics, 2023, 23 (9): e2200432.

doi: 10.1002/pmic.202200432
19
Lin J , Liu G , Chen L , et al. Targeting lactate-related cell cycle activities for cancer therapy[J]. Semin Cancer Biol, 2022, 86 (Pt 3): 1231- 1243.
20
Yang D , Yin J , Shan L , et al. Identification of lysine-lactylated substrates in gastric cancer cells[J]. iScience, 2022, 25 (7): 104630.

doi: 10.1016/j.isci.2022.104630
21
Jiang P , Ning W , Shi Y , et al. FSL-Kla: A few-shot learning-based multi-feature hybrid system for lactylation site prediction[J]. Comput Struct Biotechnol J, 2021, 19, 4497- 4509.

doi: 10.1016/j.csbj.2021.08.013
22
Liberti MV , Locasale JW . Histone lactylation: A new role for glucose metabolism[J]. Trends Biochem Sci, 2020, 45 (3): 179- 182.

doi: 10.1016/j.tibs.2019.12.004
23
Wang P , Xie D , Xiao T , et al. H3K18 lactylation promotes the progression of arsenite-related idiopathic pulmonary fibrosis via YTHDF1/m6A/NREP[J]. J Hazard Mater, 2024, 461, 132582.

doi: 10.1016/j.jhazmat.2023.132582
24
Li L , Chen K , Wang T , et al. Glis1 facilitates induction of pluripotency via an epigenome-metabolome-epigenome signalling cascade[J]. Nat Metab, 2020, 2 (9): 882- 892.

doi: 10.1038/s42255-020-0267-9
25
Kozlakidis Z , Shi P , Abarbanel G , et al. Recent developments in protein lactylation in PTSD and CVD: Novel strategies and targets[J]. BioTech, 2023, 12 (2): 38.

doi: 10.3390/biotech12020038
26
Li R , Yang Y , Wang H , et al. Lactate and lactylation in the brain: Current progress and perspectives[J]. Cell Mol Neurobiol, 2023, 43 (6): 2541- 2555.

doi: 10.1007/s10571-023-01335-7
27
Zong Z , Xie F , Wang S , et al. Alanyl-tRNA synthetase, AARS1, is a lactate sensor and lactyltransferase that lactylates p53 and contributes to tumorigenesis[J]. Cell, 2024, 187 (10): 2375- 2392.e33.

doi: 10.1016/j.cell.2024.04.002
28
Chen H , Li Y , Li H , et al. NBS1 lactylation is required for efficient DNA repair and chemotherapy resistance[J]. Nature, 2024, 631 (8021): 663- 669.

doi: 10.1038/s41586-024-07620-9
29
Chen Y , Wu J , Zhai L , et al. Metabolic regulation of homologous recombination repair by MRE11 lactylation[J]. Cell, 2024, 187 (2): 294- 311.

doi: 10.1016/j.cell.2023.11.022
30
Ali I , Conrad RJ , Verdin E , et al. Lysine acetylation goes global: From epigenetics to metabolism and therapeutics[J]. Chem Rev, 2018, 118 (3): 1216- 1252.

doi: 10.1021/acs.chemrev.7b00181
31
Moreno-Yruela C , Zhang D , Wei W , et al. Class Ⅰ histone deacetylases (HDAC1-3) are histone lysine delactylases[J]. Sci Adv, 2022, 8 (3): eabi6696.

doi: 10.1126/sciadv.abi6696
32
Walenta S , Wetterling M , Lehrke M , et al. High lactate levels predict likelihood of metastases, tumor recurrence, and restricted patient survival in human cervical cancers[J]. Cancer Res, 2000, 60 (4): 916- 921.
33
Ewaschuk JB , Naylor JM , Zello GA . D-lactate in human and ruminant metabolism[J]. J Nutr, 2005, 135 (7): 1619- 1625.

doi: 10.1093/jn/135.7.1619
34
Varner EL , Trefely S , Bartee D , et al. Quantification of lactoyl-CoA (lactyl-CoA) by liquid chromatography mass spectrometry in mammalian cells and tissues[J]. Open Biol, 2020, 10 (9): 200187.

doi: 10.1098/rsob.200187
35
Gaffney DO , Jennings EQ , Anderson CC , et al. Non-enzymatic lysine lactoylation of glycolytic enzymes[J]. Cell Chem Biol, 2020, 27 (2): 206- 213.

doi: 10.1016/j.chembiol.2019.11.005
36
Yang T , Zhang S , Nie K , et al. ZNF207-driven PRDX1 lactylation and NRF2 activation in regorafenib resistance and ferroptosis evasion[J]. Drug Resist Updat, 2025, 82, 101274.

doi: 10.1016/j.drup.2025.101274
37
Liu R , Wu J , Guo H , et al. Post-translational modifications of histones: Mechanisms, biological functions, and therapeutic targets[J]. MedComm, 2023, 4 (3): e292.

doi: 10.1002/mco2.292
38
Huang ZW , Zhang XN , Zhang L , et al. STAT5 promotes PD-L1 expression by facilitating histone lactylation to drive immuno-suppression in acute myeloid leukemia[J]. Signal Transduct Target Ther, 2023, 8 (1): 391.

doi: 10.1038/s41392-023-01605-2
39
De Leo A , Ugolini A , Yu X , et al. Glucose-driven histone lactylation promotes the immunosuppressive activity of monocyte-derived macrophages in glioblastoma[J]. Immunity, 2024, 57 (5): 1105- 1123.

doi: 10.1016/j.immuni.2024.04.006
40
Sun T , Liu B , Li Y , et al. Oxamate enhances the efficacy of CAR-T therapy against glioblastoma via suppressing ectonucleotidases and CCR8 lactylation[J]. J Exp Clin Cancer Res, 2023, 42 (1): 253.

doi: 10.1186/s13046-023-02815-w
41
Gu J , Zhou J , Chen Q , et al. Tumor metabolite lactate promotes tumorigenesis by modulating MOESIN lactylation and enhancing TGF-β signaling in regulatory T cells[J]. Cell Rep, 2022, 40 (3): 111122.

doi: 10.1016/j.celrep.2022.111122
42
Yang J , Yu X , Xiao M , et al. Histone lactylation-driven feedback loop modulates cholesterol-linked immunosuppression in pancreatic cancer[J]. Gut, 2025, 74 (11): e334361.
43
Wang J , Liu Z , Xu Y , et al. Enterobacterial LPS-inducible LINC00152 is regulated by histone lactylation and promotes cancer cells invasion and migration[J]. Front Cell Infect Microbiol, 2022, 12, 913815.

doi: 10.3389/fcimb.2022.913815
44
Zhou J , Xu W , Wu Y , et al. GPR37 promotes colorectal cancer liver metastases by enhancing the glycolysis and histone lactylation via Hippo pathway[J]. Oncogene, 2023, 42 (45): 3319- 3330.

doi: 10.1038/s41388-023-02841-0
45
Li X , Zhang C , Mei Y , et al. Irinotecan alleviates chemoresistance to anthracyclines through the inhibition of AARS1-mediated BLM lactylation and homologous recombination repair[J]. Signal Transduct Target Ther, 2025, 10 (1): 214.

doi: 10.1038/s41392-025-02302-y
46
Li F , Si W , Xia L , et al. Positive feedback regulation between glycolysis and histone lactylation drives oncogenesis in pancreatic ductal adenocarcinoma[J]. Mol Cancer, 2024, 23 (1): 90.

doi: 10.1186/s12943-024-02008-9
47
Chen M , Cen K , Song Y , et al. NUSAP1-LDHA-Glycolysis-Lactate feedforward loop promotes Warburg effect and metastasis in pancreatic ductal adenocarcinoma[J]. Cancer Lett, 2023, 567, 216285.

doi: 10.1016/j.canlet.2023.216285
48
Miao Z , Zhao X , Liu X . Hypoxia induced β-catenin lactylation promotes the cell proliferation and stemness of colorectal cancer through the Wnt signaling pathway[J]. Exp Cell Res, 2023, 422 (1): 113439.

doi: 10.1016/j.yexcr.2022.113439
49
Jin J , Bai L , Wang D , et al. SIRT3-dependent delactylation of cyclin E2 prevents hepatocellular carcinoma growth[J]. EMBO Rep, 2023, 24 (5): e56052.

doi: 10.15252/embr.202256052
50
Pandkar MR , Sinha S , Samaiya A , et al. Oncometabolite lactate enhances breast cancer progression by orchestrating histone lactylation-dependent c-Myc expression[J]. Transl Oncol, 2023, 37, 101758.

doi: 10.1016/j.tranon.2023.101758
51
Wu H , Wang Y , Ying M , et al. Lactate dehydrogenases amplify reactive oxygen species in cancer cells in response to oxidative stimuli[J]. Signal Transduct Target Ther, 2021, 6 (1): 242.

doi: 10.1038/s41392-021-00595-3
52
Maeda M , Ko M , Mane MM , et al. Genetic and drug inhibition of LDH-A: Effects on murine gliomas[J]. Cancers, 2022, 14 (9): 2306.

doi: 10.3390/cancers14092306
53
Zhang W , Wang C , Hu X , et al. Inhibition of LDHA suppresses cell proliferation and increases mitochondrial apoptosis via the JNK signaling pathway in cervical cancer cells[J]. Oncol Rep, 2022, 47 (4): 77.

doi: 10.3892/or.2022.8288
54
Jin L , Chun J , Pan C , et al. Phosphorylation-mediated activation of LDHA promotes cancer cell invasion and tumour metastasis[J]. Oncogene, 2017, 36 (27): 3797- 3806.

doi: 10.1038/onc.2017.6
55
Qiao T , Xiong Y , Feng Y , et al. Inhibition of LDHA by oxamate enhances the efficacy of anti-PD-1 treatment in an NSCLC humanized mouse model[J]. Front Oncol, 2021, 11, 632364.

doi: 10.3389/fonc.2021.632364
56
Elia I , Rossi M , Stegen S , et al. Breast cancer cells rely on environmental pyruvate to shape the metastatic niche[J]. Nature, 2019, 568 (7750): 117- 121.

doi: 10.1038/s41586-019-0977-x
57
McNeillis R , Greystoke A , Walton J , et al. A case of malignant hyperlactaemic acidosis appearing upon treatment with the mono-carboxylase transporter 1 inhibitor AZD3965[J]. Br J Cancer, 2020, 122 (8): 1141- 1145.

doi: 10.1038/s41416-020-0727-8
58
He ZX , Wei BF , Zhang X , et al. Current development of CBP/p300 inhibitors in the last decade[J]. Eur J Med Chem, 2021, 209, 112861.

doi: 10.1016/j.ejmech.2020.112861
59
Kaufman JL , Mina R , Jakubowiak AJ , et al. Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: Results of a Multiple Myeloma Research Consortium Phase Ⅰ Study[J]. Blood Cancer J, 2019, 9 (1): 3.

doi: 10.1038/s41408-018-0154-8
60
Ogura M , Ando K , Suzuki T , et al. A multicentre phase Ⅱ study of vorinostat in patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma[J]. Br J Haematol, 2014, 165 (6): 768- 776.

doi: 10.1111/bjh.12819
61
O'Connor OA , Horwitz S , Masszi T , et al. Belinostat in patients with relapsed or refractory peripheral T-cell lymphoma: Results of the pivotal phase Ⅱ BELIEF (CLN-19) study[J]. J Clin Oncol, 2015, 33 (23): 2492- 2499.

doi: 10.1200/JCO.2014.59.2782
62
Zinzani PL , Pellegrini C , Cerciello G , et al. Romidepsin in relapsed/refractory T-cell lymphomas: Italian experience and results of a named patient program[J]. Leuk Lymphoma, 2016, 57 (10): 2370- 2374.

doi: 10.3109/10428194.2015.1137292
63
Wang C , Feng F , Pan L , et al. Reply to the letter titled: Demethylzeylasteral targets lactate to suppress the tumorigenicity of liver cancer stem cells: Is it attributed to histone lactylation?[J]. Pharmacol Res, 2023, 194, 106868.

doi: 10.1016/j.phrs.2023.106868
64
Jia M , Yue X , Sun W , et al. ULK1-mediated metabolic reprogramming regulates Vps34 lipid kinase activity by its lactylation[J]. Sci Adv, 2023, 9 (22): eadg4993.

doi: 10.1126/sciadv.adg4993
[1] Hai WANG, Yizhou JIANG. Molecular mechanisms and clinical applications of anti-angiogenic therapy in precision treatment of breast cancer [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 251-256.
[2] Bixian LUO, Hongming LIU, Weixun XIE, Weihua GONG. Novel clinical insights and frontier issues in alpha- fetoprotein-producing gastric cancer [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 257-265.
[3] Wen DU, Wenbo ZHANG, Yao YU, Shuo LIU, Huiyu SU, Leihao HU, Zunan TANG, Binzhang WU, Zhen CHEN, Jiaqi LI, Hao WANG, Xin PENG. Exploration and clinical application of the "digital and intelligent surgery" diagnosis and treatment workflow for oral and maxillofacial tumors [J]. Journal of Peking University (Health Sciences), 2026, 58(2): 278-284.
[4] Ruofan GAO, Tianyu MA, Runkai WANG, Yuchen YIN, Ruidi LI, Dandan WANG, Bin XIA. Anti-inflammatory effects of cell membrane vesicle-mediated delivery of small interfering RNA targeting tumor necrosis factor-α on dental pulp stem cells [J]. Journal of Peking University (Health Sciences), 2026, 58(1): 22-29.
[5] Boda GUO, Min LU, Guoliang WANG, Hongxian ZHANG, Lei LIU, Xiaofei HOU, Lei ZHAO, Xiaojun TIAN, Shudong ZHANG. Clinicopathological and prognostic differences between clear cell and non-clear cell renal cell carcinoma with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 644-649.
[6] Zhanyi ZHANG, Min LU, Yuehao SUN, Jinghan DONG, Xiaofei HOU, Chunlei XIAO, Guoliang WANG, Xiaojun TIAN, Lulin MA, Hongxian ZHANG, Shudong ZHANG. Clinicopathological features and survival analysis of TFE3-rearranged renal cell carcinoma with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 650-661.
[7] Qi MIAO, Baoan HONG, Xuezhou ZHANG, Zhipeng SUN, Wei WANG, Yuxuan WANG, Yuxuan BO, Jiahui ZHAO, Ning ZHANG. Risk assessment of perioperative adverse events and management of antiplatelet therapy in patients with bladder cancer and coronary atherosclerotic heart disease undergoing transurethral resection of bladder cancer [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 698-703.
[8] Shuai LIU, Zhuo LIU, Yunhe GUAN, Guoliang WANG, Xiaojun TIAN, Hongxian ZHANG, Lei LIU, Lulin MA, Shudong ZHANG. Robot-assisted laparoscopic inferior vena cava segmental resection for renal tumor with tumor thrombus invading the vascular wall [J]. Journal of Peking University (Health Sciences), 2025, 57(4): 796-802.
[9] Weihao LI, Jing LI, Xuemin ZHANG, Wei LI, Qingle LI, Xiaoming ZHANG. Effect of intraoperative blood salvage autotransfusion on the prognosis of patients after carotid body tumor resection [J]. Journal of Peking University (Health Sciences), 2025, 57(2): 272-276.
[10] Yuanyuan YANG, Shanshan ZHANG, Guangyan YU, Huijun YANG, Hongyu YANG. Clinical outcomes of partial sialoadenectomy for the treatment of benign tumors in the submandibular gland [J]. Journal of Peking University (Health Sciences), 2025, 57(2): 334-339.
[11] Suqing TIAN, Haitao SUN, Tiandi ZHAO, Wei WANG. Analysis of positioning errors in head and neck cancers during radiotherapy assisted by the 6D treatment couch and image-guided radiation therapy [J]. Journal of Peking University (Health Sciences), 2024, 56(6): 1097-1100.
[12] Jiajun LIU, Guokang LIU, Yuhu ZHU. Immune-related severe pneumonia: A case report [J]. Journal of Peking University (Health Sciences), 2024, 56(5): 932-937.
[13] Kewei CHEN,Zhuo LIU,Shaohui DENG,Fan ZHANG,Jianfei YE,Guoliang WANG,Shudong ZHANG. Clinical diagnosis and treatment of renal angiomyolipoma with inferior vena cava tumor thrombus [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 617-623.
[14] Shuai LIU,Lei LIU,Zhuo LIU,Fan ZHANG,Lulin MA,Xiaojun TIAN,Xiaofei HOU,Guoliang WANG,Lei ZHAO,Shudong ZHANG. Clinical treatment and prognosis of adrenocortical carcinoma with venous tumor thrombus [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 624-630.
[15] Jie YANG,Jieli FENG,Shudong ZHANG,Lulin MA,Qing ZHENG. Clinical effects of transesophageal echocardiography in different surgical methods for nephrectomy combined with Mayo Ⅲ-Ⅳ vena tumor thrombectomy [J]. Journal of Peking University (Health Sciences), 2024, 56(4): 631-635.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
Copyright © Journal of Peking University (Health Sciences), All Rights Reserved.
Powered by Beijing Magtech Co. Ltd